Pre-existing cardiovascular disease, acute kidney injury, and cardiovascular outcomes in hospitalized blacks with COVID-19 infection.
COVID-19
Pre-existing CVD
acute kidney injury
blacks
mortality
Journal
American journal of cardiovascular disease
ISSN: 2160-200X
Titre abrégé: Am J Cardiovasc Dis
Pays: United States
ID NLM: 101569582
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
12
2020
accepted:
15
03
2021
entrez:
4
6
2021
pubmed:
5
6
2021
medline:
5
6
2021
Statut:
epublish
Résumé
The Corona Virus 19 (COVID-19) infection is associated with worse outcomes in blacks, although the mechanisms are unclear. We sought to determine the significance of black race, pre-existing cardiovascular disease (pCVD), and acute kidney injury (AKI) on cardiopulmonary outcomes and in-hospital mortality of COVID-19 patients. We conducted a retrospective cohort study of blacks with/without pCVD and with/without in-hospital AKI, hospitalized within Grady Memorial Hospital in Georgia between February and July 2020, who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on qualitative polymerase-chain-reaction assay. The primary outcome was a composite of in-hospital cardiac events. Of the 293 patients hospitalized with COVID-19 in this study, 71 were excluded from the primary analysis (for race/ethnicity other than black non-Hispanic). Of the 222 hospitalized COVID-19 patients included in our analyses, 41.4% were female, 78.8% had pCVD, and 30.6% developed AKI during the admission. In multivariable analyses, pCVD (OR 4.7, 95% CI 1.5-14.8, P=0.008) and AKI (OR 2.7, 95% CI 1.3-5.5, P=0.006) were associated with increased odds of in-hospital cardiac events. AKI was associated with increased odds of in-hospital mortality (OR 8.9, 95% CI 3.3-23.9, P<0.0001). The presence of AKI was associated with increased odds of ICU stay, mechanical ventilation, and acute respiratory distress syndrome (ARDS). pCVD and AKI were associated with higher risk of in-hospital cardiac events, and AKI was associated with a higher risk of in-hospital mortality in blacks.
Sections du résumé
BACKGROUND
BACKGROUND
The Corona Virus 19 (COVID-19) infection is associated with worse outcomes in blacks, although the mechanisms are unclear. We sought to determine the significance of black race, pre-existing cardiovascular disease (pCVD), and acute kidney injury (AKI) on cardiopulmonary outcomes and in-hospital mortality of COVID-19 patients.
METHODS
METHODS
We conducted a retrospective cohort study of blacks with/without pCVD and with/without in-hospital AKI, hospitalized within Grady Memorial Hospital in Georgia between February and July 2020, who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on qualitative polymerase-chain-reaction assay. The primary outcome was a composite of in-hospital cardiac events.
RESULTS
RESULTS
Of the 293 patients hospitalized with COVID-19 in this study, 71 were excluded from the primary analysis (for race/ethnicity other than black non-Hispanic). Of the 222 hospitalized COVID-19 patients included in our analyses, 41.4% were female, 78.8% had pCVD, and 30.6% developed AKI during the admission. In multivariable analyses, pCVD (OR 4.7, 95% CI 1.5-14.8, P=0.008) and AKI (OR 2.7, 95% CI 1.3-5.5, P=0.006) were associated with increased odds of in-hospital cardiac events. AKI was associated with increased odds of in-hospital mortality (OR 8.9, 95% CI 3.3-23.9, P<0.0001). The presence of AKI was associated with increased odds of ICU stay, mechanical ventilation, and acute respiratory distress syndrome (ARDS).
CONCLUSION
CONCLUSIONS
pCVD and AKI were associated with higher risk of in-hospital cardiac events, and AKI was associated with a higher risk of in-hospital mortality in blacks.
Types de publication
Journal Article
Langues
eng
Pagination
212-221Informations de copyright
AJCD Copyright © 2021.
Déclaration de conflit d'intérêts
None.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Eur Heart J. 2020 May 14;41(19):1798-1800
pubmed: 32186331
Am J Kidney Dis. 2018 Nov;72(5 Suppl 1):S37-S42
pubmed: 30343722
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
NCHS Data Brief. 2015 Nov;(218):1-8
pubmed: 26556175
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Curr Cardiol Rep. 2020 Apr 21;22(5):32
pubmed: 32318865
Ann Saudi Med. 2016 Jan-Feb;36(1):78-80
pubmed: 26922692
J Am Coll Cardiol. 2020 May 12;75(18):2372-2375
pubmed: 32199938
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):545-550
pubmed: 32379729
Heart. 2020 Aug;106(15):1132-1141
pubmed: 32354800
Circ Heart Fail. 2020 Jan;13(1):e006642
pubmed: 31959015
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
JAMA. 2015 Jan 20;313(3):264-74
pubmed: 25602997
J Cardiovasc Electrophysiol. 2020 May;31(5):1003-1008
pubmed: 32270559
JAMA. 2020 Apr 21;323(15):1499-1500
pubmed: 32159735
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):790-794
pubmed: 32584797
Am J Trop Med Hyg. 2020 Dec;103(6):2164-2167
pubmed: 33124548
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Herz. 2020 May;45(3):230-232
pubmed: 32140732
Ann Epidemiol. 2020 Aug;48:9-14
pubmed: 32723697
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Pathogens. 2020 Dec 15;9(12):
pubmed: 33334023
Am J Emerg Med. 2020 Jul;38(7):1504-1507
pubmed: 32317203
Prev Chronic Dis. 2020 Aug 13;17:E83
pubmed: 32790605
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Diabetes Metab Syndr. 2020 May - Jun;14(3):247-250
pubmed: 32247212
Am J Infect Control. 2021 Feb;49(2):238-246
pubmed: 32659414
Circulation. 2020 May 19;141(20):1648-1655
pubmed: 32200663
Kidney Int. 2011 Jul;80(1):17-28
pubmed: 21150873
Clin J Am Soc Nephrol. 2020 Dec 31;16(1):14-25
pubmed: 33199414
J Neuroimmune Pharmacol. 2020 Sep;15(3):359-386
pubmed: 32696264
Ann Transl Med. 2017 Jul;5(14):282
pubmed: 28828357
Chin Med J (Engl). 2020 May 5;133(9):1025-1031
pubmed: 32044814